BioPhorum CGT Regulatory Strategy workstream response to revised chapter 5.14 leading to EDQM Pharmeuropa monograph 34.3 gene therapy products for human use, chapter 5.34 and chapter 5.2.12. This content is available to BioPhorum members only.
cgt regulatory
Viewing related articles
Feedback on the WHO draft approach towards development of a global regulatory framework for CGT
Sep 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, Feedback to agency, Regulatory Strategy
A cross sub-team team of 18 members from 14 companies submitted feedback on WHO Approach towards the development of a global regulatory framework for cell and gene therapy products (document WHO/BS/2022.2424)
Feedback on FDA draft guidance on considerations for the development of CAR-T cell productsÂ
Jun 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, Feedback to agency, Regulatory Strategy
BioPhorum CGT Regulatory Strategy workstream members provide feedback on the FDA draft guidance on considerations for the development of CAR-T cell products .
Feedback on FDA draft guidance on human gene therapy products incorporating human genome editingÂ
Jun 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, Feedback to agency, Regulatory Strategy
BioPhorum CGT Regulatory Strategy workstream provided feedback on FDA draft guidance on human gene therapy products incorporating human genome editing .
Feedback on the FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early phase clinical trial
Jan 2022 | Cell & Gene Therapy, Deliverable, Feedback to agency, Regulatory Strategy
This member document summarizes consolidated feedback and recommendations from a collaboration of BioPhorum members on the FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early phase clinical trial consultation.
Feedback on FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Dec 2021 | Cell & Gene Therapy, Deliverable, Feedback to agency, Regulatory Strategy
BioPhorum members provide feedback on FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial.
Feedback on EMA draft toolbox guidance for PRIME marketing authorisation applications
Oct 2021 | Cell & Gene Therapy, Feedback to agency, Regulatory Strategy
Summary BioPhorum member only document detailing feedback and suggested recommendations on EMA draft toolbox guidance for PRIME marketing authorisation applications.
Raw Materials: Supplier change notifications: change areas and requirements
Jun 2021 | Deliverable, Drug Substance, POI - Drug Substance, Publication, Raw materials, Raw Materials Program, Supply Partner
This guidance document identifies the relevant change areas, and for each area, exemplifies the type of changes which the biopharmaceutical industry needs to be informed about. It also lists the required information, in terms of supporting data and documentation, to support notification of changes. This guidance is relevant to all raw materials used to produce biopharmaceutical products, including but not limited to cell culture media, fermentation broth components, column resin, buffers, solvents, and excipients. By highlighting the changes biopharmaceutical industry end-users need to know about and specifying the information required, the intention of this industry-aligned guidance is to reduce the quantity of rework required and the time taken to process change requests. In turn, this will reduce variability in demand patterns as end-users refrain from building extensive inventories to mitigate against the perceived risks which arise from proposed changes. While complete alignment and standardization on the information which should be provided for changes is not possible, a more robust alignment on the typical information required, as set on in this guidance, will significantly improve the current state.